<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843633</url>
  </required_header>
  <id_info>
    <org_study_id>16US01</org_study_id>
    <nct_id>NCT02843633</nct_id>
  </id_info>
  <brief_title>LEADERS FREE II: BioFreedom™ Pivotal Study</brief_title>
  <official_title>A Prospective Study of the BioFreedom™ Biolimus A9™ Drug Coated Stent in Patients at High Risk for Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the
      Gazelle™ Bare Metal Stent arm of the Leaders Free study in high bleeding risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study all patients will receive the BioFreedom™ Drug Coated Stent and one month of
      Dual Anti Platelet Therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of cardiac death and myocardial infarction at twelve months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of clinically driven target lesion revascularization at twelve months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite of cardiac death and myocardial infarction</measure>
    <time_frame>1, 2, and 6 months and 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of clinically driven target lesion revascularization</measure>
    <time_frame>1, 2, and 6 months and 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of cardiac death, myocardial infarction and stent thrombosis</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding per Bleeding Academic Research Consortium (BARC) Criteria</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis per Academic Research Consortium (ARC) Definition</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent target lesion revascularization</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization at time points other than primary endpoint</measure>
    <time_frame>followed for all target lesion revascularizations, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target vessel revascularization</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary endpoints, in patients with at least 1 lesion treated with a trial stent of 3mm or less in nominal diameter</measure>
    <time_frame>1, 2, and 6 months and 1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>High Bleeding Risk</condition>
  <arm_group>
    <arm_group_label>BioFreedom™ Drug Coated Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioFreedom™ Drug Coated Coronary Stent System</intervention_name>
    <description>a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis</description>
    <arm_group_label>BioFreedom™ Drug Coated Stent</arm_group_label>
    <other_name>Coronary Angioplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual Antiplatelet Therapy</intervention_name>
    <description>a combination of aspirin and a P2Y12 platelet receptor inhibitor</description>
    <arm_group_label>BioFreedom™ Drug Coated Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Any indication for percutaneous coronary intervention with stent placement (PCI-S) in
        patients deemed at high risk for bleeding and candidates for 1 month dual anti-platelet
        therapy (DAPT). This includes candidates with stable angina, silent ischemia, acute
        coronary syndrome (STEMI and non-STEMI), non-native lesions and in-stent restenosis.
        Patients must provide written informed consent.

        Reasons of unsuitability for &gt; 1 month dual antiplatelet treatment must include one or
        more of the following:

          1. Adjunctive oral anticoagulation treatment planned to continue after PCI

          2. Age ≥ 75 years old

          3. Baseline Hgb &lt;11 g/dl (or anemia requiring transfusion during the 4 weeks prior to
             the index procedure)

          4. Any prior intracerebral bleed

          5. Any stroke in the last 12 months

          6. Hospital admission for bleeding during the prior 12 months

          7. Non skin cancer diagnosed or treated &lt; 3 years, with a perceived increased risk for
             bleeding

          8. Planned daily Nonsteroidal anti-inflammatory drugs (NSAID) (other than aspirin) or
             steroids for &gt;30 days after PCI

          9. Planned surgery that would require interruption of DAPT (within next 6 months)

         10. Renal failure defined as: Creatinine clearance &lt;40 ml/min

         11. Thrombocytopenia (PLT &lt;100,000/mm3)

         12. Severe chronic liver disease defined as: patients who have developed any of the
             following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice

         13. Expected non-compliance to prolonged DAPT for other medical reasons

        Exclusion Criteria:

          1. Pregnant and breastfeeding women

          2. Patients expected not to comply with 1 month DAPT

          3. Patients requiring a planned staged PCI procedure more than one week after the index
             procedure

          4. Procedure planned to require non-study stents, or stand-alone plain old balloon
             angioplasty (POBA) or stand-alone atherectomy

          5. Active bleeding at the time of inclusion

          6. Reference vessel diameter &lt;2.25 - &gt;4.0mm

          7. Cardiogenic shock

          8. Compliance with long-term single anti-platelet therapy unlikely

          9. A known hypersensitivity or contraindication to aspirin, clopidogrel (or prasugrel,
             or ticagrelor if applicable), stainless steel, zinc, Biolimus A9™ or a sensitivity to
             contrast media, which cannot be adequately pre-medicated

         10. PCI during the previous 12 months for a lesion other than the target lesion of the
             index procedure

         11. Participation in another clinical trial (12 months after index procedure)

         12. Patients with a life expectancy of &lt; 12 months

         13. Patients under judicial protection, tutorship or curatorship (for France only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Leon</last_name>
    <role>Study Chair</role>
    <affiliation>CardioVascular Research Foundation, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Krucoff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Urban</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Tour</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hensley</last_name>
      <email>khensley@theheartcenter.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijana Lukovic</last_name>
      <email>Marijana.Lukovic@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute, Inc.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Knap</last_name>
      <email>Patty.Knap@tmh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidMichigan Medical Center Midland</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Whitman</last_name>
      <email>Brenda.Whitman@midmichigan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Hedrick</last_name>
      <email>tammy.hedrick@conehealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists, Ltd.</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Petersheim</last_name>
      <email>kpetersheim@berkscardiologists.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Betsill</last_name>
      <email>Kathy.Betsill@anmedhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Gruetzmacher</last_name>
      <email>CGruetzmac@regionalhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangeuil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline Hupe</last_name>
      <email>hupe.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Borlich</last_name>
      <email>martin.borlich@segebergerkliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital, Dorset Heart Centre</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Orr</last_name>
      <email>Sarah.orr@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Craigavon Cardiac Centre</name>
      <address>
        <city>Craigavon</city>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Vernon-Kelly</last_name>
      <email>Katherine.vernonkelly@southerntrust.hscni.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Tewkesbury</last_name>
      <email>Alex.anderson@goldenjubilee.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>July 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Drug Coated Stent</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The emphasis in all scientific publications and presentations will be placed on the 1-year endpoint</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
